1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsTuberculosis Research Advancement Centers (TRACs) is sponsored by National Institutes of Health. Tuberculosis Research Advancement Centers (TRACs) is a forecasted funding opportunity on Grants. gov from National Institutes of Health.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar Tuberculosis Research Advancement Centers (TRACs) (P30 Clinical Trial Not Allowed) Department of Health and Human Services National Institutes of Health Document Type:Grants Notice Funding Opportunity Number:RFA-AI-27-016 Funding Opportunity Title:Tuberculosis Research Advancement Centers (TRACs) (P30 Clinical Trial Not Allowed) Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Health Expected Number of Awards:5 Assistance Listings:93.
855 -- Allergy and Infectious Diseases Research Cost Sharing or Matching Requirement:No Last Updated Date:May 04, 2026 Original Closing Date for Applications:Jul 10, 2026 Current Closing Date for Applications:Jul 10, 2026 Archive Date:Sep 08, 2026 Estimated Total Program Funding:$ 4,000,000 Eligible Applicants:State governments Public housing authorities/Indian housing authorities Private institutions of higher education Independent school districts Native American tribal governments (Federally recognized) Special district governments City or township governments For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Additional Information on Eligibility:Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International Collaborations: Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement are not allowed. ## Additional Information Agency Name:National Institutes of Health Description:The purpose of this notice of funding opportunity (NOFO) is to support applications for the Tuberculosis (TB) Research Advancement Centers (TRACs) program.
The goal of the TRACs is to develop the next generation of TB researchers and to catalyze multidisciplinary and innovative TB science by providing expertise and resources to facilitate basic and clinical TB research. Link to Additional Information:[](https://www. grants.
gov/search-results-detail/361026) Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: National Institute of Allergy and Infectious Diseases (NIAID) TRACs Program #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below. This is being done to protect your privacy.
Unsaved changes will be lost.
According to the current listing, eligibility includes: Eligible applicant types: [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [objec…. Confirm the full requirements in the official notice before applying.
Yes — Tuberculosis Research Advancement Centers (TRACs) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article